Assessing Cancer Treatment Response to Therapy Using 18F-FSPG PET

Launched by GUY'S AND ST THOMAS' NHS FOUNDATION TRUST · May 24, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how well different imaging techniques can measure the response of certain types of cancer to treatment. Specifically, it focuses on patients with stage 3 non-small cell lung cancer (NSCLC) and stage 3 and 4 head and neck squamous cell cancer (HNSCC). The researchers will use a special imaging method called 18F-FSPG PET to see changes in the cancer cells during standard treatment, comparing the results to another method called 18F-FDG PET/CT after 12 weeks.

To participate in this trial, individuals need to be at least 16 years old, have a confirmed diagnosis of either NSCLC or HNSCC, and be starting standard treatment for the first time. They should also be able to attend all scheduled study visits and tests. However, those who are pregnant, have uncontrolled health conditions, or have had previous cancer treatments are not eligible. Participants can expect to undergo imaging scans and regular check-ups during their treatment to help researchers understand how these imaging techniques can better track cancer responses.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Written informed consent
• • 2. Aged 16 or above
• • 3. Histologically confirmed HNSCC or NSCLC, who are treatment naïve and scheduled to commence standard of care treatment ((chemo)radiotherapy)
• • 4. Willingness and ability to comply with scheduled study visits and tests
• • 5. Confirmation of adequate function of all major organs and systems
• Exclusion Criteria:
• • 1. Pregnant or lactating women
• • 2. Concomitant uncontrolled medical conditions
• • 3. Participants likely to require palliative radiotherapy within the first 12 weeks of treatment
• • 4. Prognosis less than 3 months
• • 5. Previous anti-cancer treatment (only treatment naïve patients eligible for inclusion)